Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriflunomide plus Dexamethasone in Newly Diagnosed ITP
NCT06176235Phase 2Withdrawn
- Sponsor
- Peking University People's Hospital
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of teriflunomide in immune thrombocytopenia (ITP) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Sustained Response at 24 weeks. Planned start Dec 2023; status: withdrawn.
02
Drugs
teriflunomide
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06176235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06176235.